Compare TYRA & WTTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TYRA | WTTR |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oilfield Services/Equipment |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2021 | 2017 |
| Metric | TYRA | WTTR |
|---|---|---|
| Price | $28.28 | $17.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 3 |
| Target Price | ★ $47.50 | $16.67 |
| AVG Volume (30 Days) | 807.7K | ★ 1.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 1.65% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,528,930,000.00 |
| Revenue This Year | N/A | $2.11 |
| Revenue Next Year | N/A | $4.94 |
| P/E Ratio | ★ N/A | $69.16 |
| Revenue Growth | N/A | ★ 120.79 |
| 52 Week Low | $8.98 | $7.86 |
| 52 Week High | $40.65 | $20.48 |
| Indicator | TYRA | WTTR |
|---|---|---|
| Relative Strength Index (RSI) | 42.75 | 44.41 |
| Support Level | $27.40 | $16.26 |
| Resistance Level | $31.57 | $18.50 |
| Average True Range (ATR) | 1.98 | 0.63 |
| MACD | 0.26 | -0.19 |
| Stochastic Oscillator | 42.12 | 18.36 |
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
Select Water Solutions Inc provides sustainable water-management solutions to the energy industry in the United States. These solutions are supported by the company's critical water infrastructure assets, chemical manufacturing, and water treatment and recycling capabilities. The company's reportable segments are Water Services, Water Infrastructure, and Chemical Technologies. It generates maximum revenue from the Water Services segment, which comprises its short-cycle, field-based service offerings, including water transfer, water sourcing, fluids hauling, monitoring, containment, water-network automation, and the services associated with Peak Rentals. This segment earns revenue via market-based day rates, time-and-materials, or per-barrel delivered under MSAs and short-term work orders.